Control of energy metabolism by changes of the organ lipid quality through fatty acid elongase Elovl6.

Elovl6是一种微粒体酶，参与具有12、14和16个碳的饱和和单不饱和脂肪酸的延伸。本研究通过肝特异性Elovl6缺陷小鼠（LKO）、脑特异性Elovl6缺陷小鼠（BKO）和Elovl6^<-/->骨髓细胞移植LDLR^<-/->小鼠，旨在阐明Elovl6在肝脏、摄食行为和动脉粥样硬化中的生理作用。高糖饮食对LKO小鼠的胰岛素敏感性高于flox小鼠。BKO小鼠表现出饮食偏好的变化。移植LDLR^<-/->骨髓细胞的Elovl6^<-/->小鼠主动脉粥样硬化病变区域明显小于野生型小鼠。这些结果表明，抑制Elovl6活性可能通过避免肥胖问题，为治疗胰岛素抵抗、糖尿病、代谢综合征和心血管风险提供一种新的治疗方法。

Elovl6 is a microsomal enzyme involved in the elongation of saturated and monounsaturated FAs with 12, 14, and 16 carbons. In this research, we generated liver-specific Elovl6 deficient mice (LKO), brain-specific Elovl6 deficient mice (BKO), and Elovl6^<-/-> bone marrow cells-transplanted LDLR^<-/-> mice, and aimed to elucidate the physiological role of Elovl6 in the liver, feeding behavior, and atherosclerosis. High sucrose diet-feeding in LKO mice caused higher insulin sensitivity than those of flox mice. BKO mice showed the change of dietary preference. Aortic atherosclerotic lesion areas were significantly smaller in Elovl6^<-/-> bone marrow cells-transplanted LDLR^<-/-> mice than in wild-type. These results suggest that inhibiting Elovl6 activity may provide a novel therapeutic approach for treating insulin resistance, diabetes, metabolic syndrome, and cardiovascular risks by circumventing obesity problems.